Skip to main content
. 2023 Mar 13;324(5):R635–R644. doi: 10.1152/ajpregu.00189.2022

Figure 4.

Figure 4.

Confirmation of GFRALDTR neuron ablation confirmation. Body weights of GFRAL WT and GFRAL DTR mice dosed with subcutaneous vehicle or 0.4 mg/kg GDF15 daily on days 1, 2, and 3 (A) and cumulative food intake at 48 h (B) and 72 h (C; n = 6–7/group); two-way ANOVA with Tukey’s post hoc test. *P < 0.05 compared with GFRALWT GDF15 treated. Representative immunostaining (100 μm scale bar) of the AP/NTS and PBN labeling GFRAL neurons (eGFP) and cFOS 4 h after GDF15 treatment in GFRAL DTR and GFRAL WT mice (D). Quantification of immunostained cells labeling GFP (E) and cFOS (F) in the AP and NTS from mice dosed with GDF15 (n = 5–6 mice/group); one-way ANOVA. **P < 0.01; ****P < 0.0001 compared with GFRAL WT. CTA of WT and GFRAL DTR mice conditioned to GDF15 at 4 h after presentation of two-bottle choices (G) two-way ANOVA. ****P < 0.0001 compared with GFRAL WT. All data are represented as means ± SE; AP, area postrema; CTA, conditioned taste avoidance; DTR, diphtheria toxin receptor; GFRAL,GDNF family receptor α-like; NTS, nucleus of the solitary tract; WT, wild type; PBN, parabrachial nucleus.